Sign in

You're signed outSign in or to get full access.

PP

PMV Pharmaceuticals, Inc. (PMVP)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 was execution-heavy: enrollment in the pivotal Phase 2 PYNNACLE trial remained on track; cash, cash equivalents, and marketable securities were $165.8M with runway to end of 2026 .
  • EPS of $-0.34 beat Wall Street consensus EPS of $-0.383 (3 estimates) as operating discipline offset higher R&D; revenue remains $0 given clinical-stage status .
  • Management reiterated mid-2025 interim analysis timing and clarified scope (~50 patients, ≥18 weeks follow-up), a major upcoming catalyst, with ~40% ovarian cohort representation .
  • Spend mix shifted toward clinical operations: R&D rose to $17.4M (+$4.3M YoY), while G&A declined to $4.1M on headcount and facility savings .
  • No call transcript was published for Q1; narrative came from the press release and 10-Q. The next stock-moving catalyst is the Phase 2 interim analysis data release mid-year .

What Went Well and What Went Wrong

What Went Well

  • Pivotal trial execution: “Our registrational PYNNACLE trial continues to progress well and enrollment remains on track,” said CEO David Mack .
  • Cash runway and liquidity: $165.8M cash/equivalents/marketable securities, sufficient runway to end of 2026 .
  • Defined interim analysis scope: mid-2025 readout for ~50 patients (≥18 weeks), with ~40% ovarian cohort—adds visibility to the data catalyst .

What Went Wrong

  • Higher R&D spend widened loss: R&D rose to $17.4M (+$4.3M YoY), driving net loss to $17.4M versus $15.3M in Q1 2024 .
  • Interest income declined YoY: interest income fell to $1.9M from $3.0M on lower rates and portfolio positioning .
  • Macro/trade risks: the company highlighted potential tariff and China manufacturing exposure, noting new U.S. tariff regimes and investigations that could affect inputs and costs .

Financial Results

Quarterly trend: Revenue, EPS, operating spend, liquidity

MetricQ2 2024Q3 2024Q1 2025
Revenue ($USD Millions)$0.0 $0.0 $0.0
EPS (Net loss per share, $)$-0.02 $-0.37 $-0.34
R&D Expense ($USD Millions)$14.63 $16.95 $17.44
G&A Expense ($USD Millions)$5.54 $4.94 $4.12
Cash + Equivalents + Marketable Securities ($USD Millions)$212.9 $197.9 $165.8
Net Cash Used in Operations ($USD Millions)$17.8 (six months) $34.6 (nine months) $18.3 (quarter)

Q1 2025 YoY and vs. estimates

MetricQ1 2024Q1 2025Consensus (Q1 2025)
Revenue ($USD Millions)$0.0 $0.0 $0.0*
EPS (Net loss per share, $)$-0.30 $-0.34 $-0.383*
R&D Expense ($USD Millions)$13.19 $17.44 N/A
G&A Expense ($USD Millions)$5.04 $4.12 N/A
Interest Income ($USD Millions)$2.95 $1.94 N/A
Income Tax (Benefit) ($USD Millions)$0.00 $(2.20) N/A

Values retrieved from S&P Global for consensus estimates.*

Highlights: EPS beat by ~$0.04 versus consensus (less negative), while revenue remains $0 given clinical-stage status .
R&D intensity increased YoY as Phase 2 operations scaled; G&A declined YoY after 2024 restructuring and facility changes .

KPIs (clinical and operating)

KPIQ2 2024Q3 2024Q1 2025
Phase 2 sites activated>60% >75% >90% (as of FY update)
Interim analysis timingMid-2025 Mid-2025 Mid-2025; ~50 patients; ≥18 weeks follow-up
Cash runwayEnd of 2026 End of 2026 End of 2026

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Interim analysis timingMid-2025Mid-2025 (timing only) Mid-2025 with ~50 patients, ≥18 weeks follow-up; ~40% ovarian cohort Clarified scope/size (raised specificity)
Cash runwayThrough end-2026End-2026 End-2026 Maintained
NDA timingNDA filing by end-2026By end-2026 By end-2026 Maintained
Site activationGlobal activation progress>75% >90% activated across regions (FY update) Raised/advanced

Earnings Call Themes & Trends

No Q1 2025 earnings call transcript was available in the document catalog; themes are synthesized from the press release and 10-Q .

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q1 2025)Trend
Pivotal Phase 2 executionEnrollment/site activation progressing; >60–75% activated; interim mid-2025 Enrollment on track; interim mid-2025 with defined patient cohort Positive execution; greater visibility
Regulatory pathwayNDA targeted by end-2026 NDA targeted by end-2026 reaffirmed Maintained
R&D spend and operating disciplineR&D rising with trial scale; G&A declining R&D up YoY; G&A down YoY; tax benefit in Q1 Mix shift to clinical ops
Supply chain/trade exposure—Highlighted China/tariff risks; potential cost impacts Risk awareness elevated
AML/MDS expansion (investigator-led)Planned start in 1Q25 First patient dosed in 1Q25 at MDACC Progressing

Management Commentary

  • “Our registrational PYNNACLE trial continues to progress well and enrollment remains on track… We look forward to providing data from the interim analysis in the middle of this year.” — David Mack, Ph.D., President & CEO .
  • Corporate update emphasized liquidity: “Cash, cash equivalents, and marketable securities of $165.8 million… providing expected cash runway to end of 2026.” .
  • Program clarity: interim analysis will cover ~50 patients (≥18 weeks), ~40% ovarian cohort .

Q&A Highlights

  • No Q1 2025 earnings call transcript was published; no public Q&A content available in the document set (ListDocuments returned 0 earnings-call-transcript items for 2025) [ListDocuments result].

Estimates Context

  • Q1 2025 EPS: actual $-0.34 vs consensus $-0.383 (3 estimates); modest beat likely reflects lower G&A and tax benefit, partially offset by higher R&D .
  • Revenue estimates are effectively zero for a clinical-stage company; actual revenue remains $0 .

Values retrieved from S&P Global for consensus estimates.*

Key Takeaways for Investors

  • Near-term catalyst: mid-2025 Phase 2 interim analysis with ~50 patients (≥18 weeks)—expect stock reaction to response-rate quality, cohort-level signals (notably ovarian), and safety profile .
  • Spending trajectory consistent with trial advancement: rising R&D with reduced G&A; monitor cash burn vs runway (end-2026) and optionality around ATM capacity ($113.8M available as of 3/31/25) .
  • EPS beat suggests estimates may drift modestly less negative near term; revenue remains non-informative pre-approval .
  • Regulatory timeline intact (NDA by end-2026); interim analysis specificity adds confidence in program cadence .
  • Watch macro/trade headlines: tariff regime changes and China exposure could influence input costs and supply chain reliability for chemistry/manufacturing .
  • Non-oncology expansion: AML/MDS investigator-led combo program initiated; read-throughs could broaden future label scope if efficacy emerges .
  • Position sizing considerations: binary data risks remain; liquidity adequate for planned operations, but data quality will drive financing path and valuation .

Sources

  • Q1 2025 8-K and Exhibit 99.1 press release:
  • Q1 2025 standalone press release:
  • Q1 2025 10-Q and MD&A:
  • FY 2024 press release (context):
  • Q3 2024 press release (trend):
  • Q2 2024 press release (trend):

Values retrieved from S&P Global for consensus estimates.*